Valerijus Ostapenko

1.1k total citations
21 papers, 696 citations indexed

About

Valerijus Ostapenko is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Valerijus Ostapenko has authored 21 papers receiving a total of 696 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 10 papers in Cancer Research and 7 papers in Molecular Biology. Recurrent topics in Valerijus Ostapenko's work include Breast Cancer Treatment Studies (5 papers), Cancer survivorship and care (4 papers) and HER2/EGFR in Cancer Research (4 papers). Valerijus Ostapenko is often cited by papers focused on Breast Cancer Treatment Studies (5 papers), Cancer survivorship and care (4 papers) and HER2/EGFR in Cancer Research (4 papers). Valerijus Ostapenko collaborates with scholars based in Lithuania, United Kingdom and France. Valerijus Ostapenko's co-authors include Aida Laurinavičienė, Arvydas Laurinavičius, Sonata Jarmalaitė, H. J. Illiger, Nathalie Bardy‐Bouxin, S. Johnston, Christian Dittrich, Marc Salzberg, K. Mross and Fátima Cardoso and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Scientific Reports.

In The Last Decade

Valerijus Ostapenko

20 papers receiving 674 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Valerijus Ostapenko Lithuania 10 357 292 148 142 87 21 696
Mark Opdam Netherlands 15 278 0.8× 273 0.9× 201 1.4× 101 0.7× 51 0.6× 32 570
Satoko Yamamoto Japan 18 301 0.8× 213 0.7× 148 1.0× 86 0.6× 119 1.4× 35 648
Francisco Beça United States 16 383 1.1× 321 1.1× 353 2.4× 120 0.8× 55 0.6× 33 829
Syed A. Ahmed United States 10 224 0.6× 304 1.0× 149 1.0× 107 0.8× 26 0.3× 16 644
Beatrix Elsberger United Kingdom 14 289 0.8× 386 1.3× 182 1.2× 85 0.6× 63 0.7× 40 735
Run-Fen Cheng China 16 425 1.2× 204 0.7× 168 1.1× 149 1.0× 164 1.9× 38 757
Sharon B. Sams United States 17 382 1.1× 514 1.8× 229 1.5× 208 1.5× 53 0.6× 40 1.0k
Zora Nešković‐Konstantinović Serbia 14 338 0.9× 419 1.4× 144 1.0× 220 1.5× 46 0.5× 49 698
Izo Kimijima Japan 16 317 0.9× 330 1.1× 272 1.8× 100 0.7× 111 1.3× 65 872
Margarita Viladot Spain 6 379 1.1× 464 1.6× 449 3.0× 185 1.3× 91 1.0× 12 905

Countries citing papers authored by Valerijus Ostapenko

Since Specialization
Citations

This map shows the geographic impact of Valerijus Ostapenko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Valerijus Ostapenko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Valerijus Ostapenko more than expected).

Fields of papers citing papers by Valerijus Ostapenko

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Valerijus Ostapenko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Valerijus Ostapenko. The network helps show where Valerijus Ostapenko may publish in the future.

Co-authorship network of co-authors of Valerijus Ostapenko

This figure shows the co-authorship network connecting the top 25 collaborators of Valerijus Ostapenko. A scholar is included among the top collaborators of Valerijus Ostapenko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Valerijus Ostapenko. Valerijus Ostapenko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Daniūnaitė, Kristina, et al.. (2022). Analysis of Intrinsic Breast Cancer Subtypes: The Clinical Utility of Epigenetic Biomarkers and TP53 Mutation Status in Triple-Negative Cases. International Journal of Molecular Sciences. 23(23). 15429–15429. 2 indexed citations
2.
Ostapenko, Valerijus, et al.. (2022). Malignant phyllodes tumor of the breast with metastases to the lungs: A case report and literature review. SHILAP Revista de lepidopterología. 17(10). 4006–4012. 3 indexed citations
3.
4.
Daniūnaitė, Kristina, et al.. (2021). Nongenotoxic ABCB1 activator tetraphenylphosphonium can contribute to doxorubicin resistance in MX-1 breast cancer cell line. Scientific Reports. 11(1). 6556–6556. 7 indexed citations
5.
Rasmusson, Allan G., et al.. (2020). Immunogradient Indicators for Antitumor Response Assessment by Automated Tumor-Stroma Interface Zone Detection. American Journal Of Pathology. 190(6). 1309–1322. 27 indexed citations
6.
Rasmusson, Allan G., Justinas Besusparis, Aida Laurinavičienė, et al.. (2020). Independent Prognostic Value of Intratumoral Heterogeneity and Immune Response Features by Automated Digital Immunohistochemistry Analysis in Early Hormone Receptor-Positive Breast Carcinoma. Frontiers in Oncology. 10. 950–950. 23 indexed citations
7.
Didžiapetrienė, Janina, et al.. (2020). Oxidant/Antioxidant Status of Breast Cancer Patients in Pre- and Post-Operative Periods. Medicina. 56(2). 70–70. 22 indexed citations
8.
Dulskas, Audrius, et al.. (2019). Surgery for triple-negative breast cancer- does the type of anaesthesia have an influence on oxidative stress, inflammation, molecular regulators, and outcomes of disease?. PubMed. 23(2). 290–295. 9 indexed citations
9.
Kuzmickienė, Irena, Vydmantas Atkočius, Eduardas Aleknavičius, & Valerijus Ostapenko. (2018). Impact of season of diagnosis on mortality among breast cancer survivors. Journal of Cancer Research and Therapeutics. 14(12). 1091–1091. 6 indexed citations
10.
Pautier, Patricia, Ignace Vergote, Florence Joly, et al.. (2016). A Phase 2, Randomized, Open-Label Study of Irosustat Versus Megestrol Acetate in Advanced Endometrial Cancer. International Journal of Gynecological Cancer. 27(2). 258–266. 32 indexed citations
11.
12.
Laurinavičius, Arvydas, Andrew R. Green, Aida Laurinavičienė, et al.. (2015). Ki67/SATB1 ratio is an independent prognostic factor of overall survival in patients with early hormone receptor-positive invasive ductal breast carcinoma. Oncotarget. 6(38). 41134–41145. 15 indexed citations
13.
Daniūnaitė, Kristina, et al.. (2013). High-Resolution Melting-Based Quantitative Analysis of RASSF1 Methylation in Breast Cancer. Medicina. 49(2). 14–14. 7 indexed citations
14.
Laurinavičius, Arvydas, Aida Laurinavičienė, Valerijus Ostapenko, et al.. (2012). Immunohistochemistry profiles of breast ductal carcinoma: factor analysis of digital image analysis data. Diagnostic Pathology. 7(1). 27–27. 54 indexed citations
15.
16.
Ostapenko, Valerijus, et al.. (2011). Išplitusio sensibilizuoto krūties vėžio diagnostika ir gydymas. 9(3-4). 0–0. 1 indexed citations
17.
Ostapenko, Valerijus, et al.. (2007). Quality of life of Lithuanian women with early stage breast cancer. BMC Public Health. 7(1). 124–124. 15 indexed citations
18.
Chan, Stephen, M. E. Scheulen, S. Johnston, et al.. (2005). Phase II Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast Cancer. Journal of Clinical Oncology. 23(23). 5314–5322. 386 indexed citations
19.
Ostapenko, Valerijus, et al.. (2005). Influence of social factors on the quality of life after breast cancer surgical treatment. 6 indexed citations
20.
Vinholes, J., Fernando Palacios Salas, E. Mickiewicz, et al.. (2001). A phase III trial of taxotere and doxorubicin (AT) versus 5-fluorouracil, doxorubicin and cyclophosphamide (FAC) in patients with unresectable locally advanced breast cancer: an interim analysis. European Journal of Cancer. 37. S167–S167. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mark Opdam Breakdown of academic impact, for papers by Satoko Yamamoto Breakdown of academic impact, for papers by Francisco Beça Breakdown of academic impact, for papers by Syed A. Ahmed Breakdown of academic impact, for papers by Beatrix Elsberger Breakdown of academic impact, for papers by Run-Fen Cheng Breakdown of academic impact, for papers by Sharon B. Sams Breakdown of academic impact, for papers by Zora Nešković‐Konstantinović Breakdown of academic impact, for papers by Izo Kimijima Breakdown of academic impact, for papers by Margarita Viladot
Rankless by CCL
2026